EL Stock Analysis: EssilorLuxottica S. A. | PA
Medical Instruments & Supplies | PA, France | Market Cap: 67.020m EUR | 12M Return: -46.4% | FR0000121667 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 119M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
EssilorLuxottica Société anonyme is a Paris-headquartered, France-domiciled company that designs, manufactures, and distributes ophthalmic lenses, frames, sunglasses, and related instruments and equipment. It operates across North America, the Middle East, Africa, Europe, Latin America, and Asia-Pacific, serving the global eyecare and eyewear industry.
The company sells a wide portfolio of proprietary and licensed brands, including Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Costa, Bolon, and Foster Grant on the eyewear side, and Essilor, Varilux, Crizal, Eyezen, Stellest, Transitions, Nikon, and KODAK Lens on the lens side. It also markets contact lenses and reading glasses, alongside diagnostic and clinical brands such as Humanware.
Beyond finished eyewear, EssilorLuxottica produces vision-assessment equipment, optical instruments, and consumables for opticians and laboratories, including imaging platforms like SPECTRALIS and ANTERION, lens-edging and mounting tools, and the Satisloh range of surfacing, polishing, and coating equipment. Distribution reaches independent opticians, distributors, third-party e-commerce platforms, and large retail chains, as well as consumers through physical retail networks and online channels.
The company was founded in 1849 and took its current name in October 2018 following the combination of lens maker Essilor International and eyewear/retail group Luxottica, creating one of the most vertically integrated players in the global optical industry, spanning lens manufacturing, frame design, brand ownership, retail, and in-office equipment.
- Ray-Ban Meta smart glasses sales accelerate
- Branded eyewear margins expand on premium mix
- Stellest myopia lens demand grows in Asia
| Net Income: 2.49b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.48 > 1.0 |
| NWC/Revenue: -4.80% < 20% (prev -1.32%; Δ -3.48% < -1%) |
| CFO/TA 0.08 > 3% & CFO 5.29b > Net Income 2.49b |
| Net Debt (17.3b) to EBITDA (6.78b): 2.55 < 3 |
| Current Ratio: 0.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (464.4m) vs 12m ago 1.27% < -2% |
| Gross Margin: 60.84% > 18% (prev 62.44%; Δ -1.60% > 0.5%) |
| Asset Turnover: 46.12% > 50% (prev 43.99%; Δ 2.13% > 0%) |
| Interest Coverage Ratio: 10.20 > 6 (EBIT TTM 3.62b / Interest Expense TTM 355.0m) |
| A: -0.02 (Total Current Assets 11.2b - Total Current Liabilities 12.6b) / Total Assets 65.1b |
| B: 0.26 (Retained Earnings 16.6b / Total Assets 65.1b) |
| C: 0.06 (EBIT TTM 3.62b / Avg Total Assets 63.5b) |
| D: 1.56 (Book Value of Equity 39.2b / Total Liabilities 25.1b) |
| Altman-Z'' = 2.71 = A |
| DSRI: 0.93 (Receivables 3.99b/4.01b, Revenue 29.3b/27.2b) |
| GMI: 1.03 (GM 62.44% / 60.84%) |
| AQI: 1.00 (AQ_t 0.68 / AQ_t-1 0.68) |
| SGI: 1.07 (Revenue 29.3b / 27.2b) |
| TATA: -0.04 (NI 2.49b - CFO 5.29b) / TA 65.1b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of October 06, 2026, the stock is trading at EUR 144.50 with a total of 626,260 shares traded. Over the past week, the price has changed by -1.10%, over one month by -2.73%, over three months by -16.28% and over the past year by -46.43%.
Current recommended Stop Loss: 139.40 (which is 3.5% or 1.3 ATR below the current price).
EssilorLuxottica S. A. has no consensus analysts rating.
P/E Trailing = 27.3084
P/E Forward = 17.7305
P/S = 2.2886
P/B = 1.754
P/EG = 1.584
Revenue TTM = 29.3b EUR
EBIT TTM = 3.62b EUR
EBITDA TTM = 6.78b EUR
Long Term Debt = 6.73b EUR (from longTermDebt, last quarter)
Short Term Debt = 5.66b EUR (from shortTermDebt, last quarter)
Debt = 19.2b EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.91b
Net Debt = 17.3b EUR (calculated: Debt 19.2b - CCE 1.93b)
Enterprise Value = 84.3b EUR (67.0b + Debt 19.2b - CCE 1.93b)
Interest Coverage Ratio = 10.20 (Ebit TTM 3.62b / Interest Expense TTM 355.0m)
EV/FCF = 21.94x (Enterprise Value 84.3b / FCF TTM 3.84b)
FCF Yield = 4.56% (FCF TTM 3.84b / Enterprise Value 84.3b)
FCF Margin = 13.12% (FCF TTM 3.84b / Revenue TTM 29.3b)
Net Margin = 8.52% (Net Income TTM 2.49b / Revenue TTM 29.3b)
Gross Margin = 60.84% ((Revenue TTM 29.3b - Cost of Revenue TTM 11.5b) / Revenue TTM)
Gross Margin QoQ = 63.47% (prev 58.15%)
Tobins Q-Ratio = 1.30 (Enterprise Value 84.3b / Total Assets 65.1b)
Interest Expense / Debt = 1.85% (Interest Expense 355.0m / Debt 19.2b)
Taxrate = 23.99% (831.0m / 3.46b)
NOPAT = 2.75b (EBIT 3.62b * (1 - 23.99%))
Current Ratio = 0.89 (Total Current Assets 11.2b / Total Current Liabilities 12.6b)
Debt / Equity = 0.49 (Debt 19.2b / totalStockholderEquity, last quarter 39.2b)
Debt / EBITDA = 2.55 (Net Debt 17.3b / EBITDA 6.78b)
Debt / FCF = 4.50 (Net Debt 17.3b / FCF TTM 3.84b)
Total Stockholder Equity = 39.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.93% (Net Income 2.49b / Total Assets 65.1b)
RoE = 6.38% (Net Income TTM 2.49b / Total Stockholder Equity 39.1b)
RoCE = 7.90% (EBIT 3.62b / Capital Employed (Equity 39.1b + L.T.Debt 6.73b))
RoIC = 4.86% (NOPAT 2.75b / Invested Capital 56.6b)
WACC = 6.21% (E(67.0b)/V(86.2b) * Re(7.59%) + D(19.2b)/V(86.2b) * Rd(1.85%) * (1-Tc(0.24)))
Discount Rate = 7.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.34 | Cagr: 1.87%
[DCF] Terminal Value 77.85% ; FCFF base≈3.65b ; Y1≈4.16b ; Y5≈6.02b
[DCF] Fair Price = 160.1 (EV 90.7b - Net Debt 17.3b = Equity 73.4b / Shares 458.7m; r=8.35% [WACC [floored]]; 5y FCF grow 14.24% → 2.50% )
EPS Correlation: -54.48 | EPS CAGR: -0.99% | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.09 | Revenue CAGR: 6.08% | SUE: 1.23 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=7.28 | Chg30d=-1.66% | Revisions=+0% | GrowthEPS=+7.2% | GrowthRev=+6.0%
EPS next Year (2027-12-31): EPS=7.98 | Chg30d=-1.69% | Revisions=+0% | GrowthEPS=+9.6% | GrowthRev=+8.5%
[Analyst] Revisions Ratio: +0% (up=2, down=2)